Holen Sie sich die Stockscreener-App
22.91
3.60%
0.81
Schlusskurs vom Vortag:
$22.10
Offen:
$22.12
24-Stunden-Volumen:
284.19K
Relative Volume:
0.32
Marktkapitalisierung:
$940.98M
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
15.80
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-2.41%
1M Leistung:
+10.71%
6M Leistung:
-14.35%
1J Leistung:
-2.70%
1-Tages-Spanne:
$21.87
$22.93
1-Wochen-Bereich:
$20.62
$23.73
52-Wochen-Spanne:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.89 | 908.31M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
PCRX Earnings History & Surprises | EPS & Revenue Results | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - Sahm
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - Sahm
Pacira BioSciences Q4 Earnings Call Highlights - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira BioSciences Inc. (PCRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Q4 Earnings Assessment - Benzinga
BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million - TradingView
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside - DirectorsTalk Interviews
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Pacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Can Pacira BioSciences Inc expand its profit margins2025 Valuation Update & Detailed Earnings Play Alerts - baoquankhu1.vn
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court - TipRanks
Can Pacira BioSciences Inc. stock deliver sustainable ROEQuarterly Profit Review & AI Driven Stock Reports - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
MSN Money - MSN
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Closer Look at Its 36.49% Potential Upside - DirectorsTalk Interviews
Is Pacira BioSciences Inc. trading at a discountEarnings Risk Report & Consistent Profit Trade Alerts - mfd.ru
Understanding Momentum Shifts in (PCRX) - Stock Traders Daily
Will Pacira BioSciences Inc. (82P) stock gain from lower interest ratesWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Should you avoid Pacira BioSciences Inc. stock right nowLong Setup & AI Enhanced Trading Signals - mfd.ru
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Should you avoid Pacira BioSciences Inc stock right nowJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ: PCRX) grants CFO 49,091 restricted stock units - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 - GlobeNewswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):